iPSC Characterization Kit Market Size, Share and Trends Analysis to 2030 – openPR

iPSC Characterization Kit Market to Record an Exponential CAGR by 2030 - Exclusive Report by InsightAce Analytic

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Value-Based Healthcare Services Market By Type (Alkaline Phosphatase Staining Assay, Pluripotency Markers (Protein) And Pluripotency Markers (Mrna)), Application (Cancer Research Center, Pathology Laboratory, Academic And Research, Contract Research Organizations And Others)- Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

The global iPSC characterization kit market is estimated to exhibit a CAGR of 6.87% during the forecast period.

Get Free Sample Copy of Report :https://www.insightaceanalytic.com/request-sample/1418

The iPSC characterization kit (Induced pluripotent stem cell) contains several delicate tools for phenotypic characterization of the pluripotent state of human embryonic stem & induced pluripotent stem cells. Induced pluripotent stem cells (iPSCs) have several benefits over embryonic stem cells (ESCs), including avoiding ethical issues with stem cells and providing the most flexibility for use in cell-based research. In recent years, these advantages have significantly increased the popularity of induced pluripotent stem cells (iPSCs), creating a promising market for iPSC characterization kits. The robust pipeline for iPSC-derived cell treatments and innovative iPSC applications is anticipated to hasten market expansion. Furthermore, a rise in the incidence of chronic diseases is contributing to the market growth for iPSC characterization kits. The market for iPSC characterization kits is being driven by the use of induced pluripotent stem cells to treat chronic diseases like diabetes, cancer, cancer, and heart disease. This rise in the incidence of chronic diseases is fueling the rising need for induced pluripotent stem cell therapy, which supports the growth of the iPSC characterization kit market.

List of Prominent Players in the IPSC Characterization Kit Market:Merck KGaATakara BioThermo Fisher ScientificBD BiosciencesApplied StemCellAmsbioBio-TechneALSTEMSTEMCELL TechnologiesSystem BiosciencesApplied Biological MaterialsCreative BioarrayElixirgen ScientificMiltenyi Biotec

Market Dynamics:Drivers- The market for iPSC characterization kits is driven by the expanding utilization of induced pluripotent stem cells (iPSCs), the developing biotechnology sector with better investment, and the rising prevalence of chronic diseases. The broad range of clinical applications of induced pluripotent stem cells and recent technological developments of iPSCs are two additional reasons that are projected to fuel the expansion of the global iPSC characterization kit market.

ChallengesThe availability of alternatives for tumor therapy and the high cost of stem cell therapies are two factors restraining the growth of the worldwide iPSC characterization kit market. The main market hurdle in the global iPSC characterization kit market is the strict laws and regulations and the genomic instability of iPSC. Induced pluripotent stem cell growth is significantly constrained by the possibility of tumor development, which also inhibits the market expansion for iPSC characterization kits.

Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1418

Regional Trends:The North American iPSC characterization kit market is expected to register a significant market share in revenue and is projected to grow at a high CAGR shortly. Significant commercial and public finance for research institutes is fundamental in this situation, and essential industry firms are well represented in the region. Additionally, a robust R&D infrastructure and various application scenarios, such as tissue engineering and toxicity screening, support the market growth for iPSC characterization kits. It is anticipated that the area will continue to dominate. Besides, Asia Pacific had a substantial share in the iPSC characterization kit market. The adoption of induced pluripotent stem cells is predicted to be supported by robust market expansion in countries like Japan and China and increased interest in regenerative medicine in the region, which will further fuel the growth of the iPSC characterization kit market. Regional governments are working together to change the fact that there isn't a clear legal framework for the iPSC industry. Their efforts will be anticipated to aid in the market growth for iPSC characterization kits.

Segmentation of iPSC Characterization Kit Market-By Type-Alkaline Phosphatase Staining AssayPluripotency Markers (Protein)Pluripotency Markers (mRNA)By Application-Cancer Research CenterPathology LaboratoryAcademic and ResearchContract Research OrganizationsOthersBy Region-North America-The USCanadaMexicoEurope-Germany The UKFranceItaly Spain Rest of EuropeAsia-Pacific-ChinaJapan IndiaSouth KoreaSouth East AsiaRest of Asia PacificLatin America-BrazilArgentinaRest of Latin America Middle East & Africa-GCC CountriesSouth Africa Rest of Middle East and Africa

For More Customization @ https://www.insightaceanalytic.com/customisation/1418

Corporate Office :Office No.3050, 3rd Floor Marvel Fuego, Magarpatta Rd, Hadapsar, Pune, Maharashtra 411028

Sales Office (U.S.) :344 Grove St Unit #967 Jersey City, NJ 07302info@insightaceanalytic.com

info@insightaceanalytic.comNorth America:+1 551 226 6109Asia:+91 79 72967118

This release was published on openPR.

Read more:
iPSC Characterization Kit Market Size, Share and Trends Analysis to 2030 - openPR

Epigenetic Regulation Studied at the Single-Molecule Level – Technology Networks

Register for FREE to listen to this article

Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

In a first-of-its-kind study, EMBL researchers have shown how DNA methylation across the genome contributes to the precise regulation of gene expression.

If one imagines the genome as an instruction manual for the functioning of a cell, every page of this manual is covered with annotations, highlights, and bookmarks. The role of some of these marks remains mysterious do they actively direct the reader to the right place at the right time, or do they merely indicate the pages the reader has already visited?

Subscribe to Technology Networks daily newsletter, delivering breaking science news straight to your inbox every day.

This subtle distinction in the language of the cell can play an important role in its survival and function. As researchers from theKrebs groupat EMBL Heidelberg have now shown, one such annotation DNA methylation exerts a highly selective layer of control on the expression of genes, one that varies according to cell type and fate.

In the analogy above, the annotations, highlights, and bookmarks represent what scientists call epigenetic marks, whereas the reader is usually the complex molecular machinery responsible for gene expression. The latter includes specialised proteins known as transcription factors.

When a particular region of DNA needs to be expressed, the area surrounding it undergoes physical and chemical changes, making it more accessible to such molecular machines. While DNA methylation is found across the genome, whether and how it affects this accessibility at specific genomic regions remains relatively unexplored.

Our group is interested in the fundamental mechanisms that regulate gene expression, said Arnaud Krebs, Group Leader at EMBL Heidelberg. We are particularly interested incis-regulatory elements like enhancers DNA regions that control the activity of genes.

Krebs team was intrigued by the fact that while DNA methylation is often reduced at active enhancers, the cause-effect relationship between the two remains unclear. Does the activation of these DNA regions lead to a removal of methylation? Or does the reduction in methylation itself drive the activation?

To investigate this, the team used a high-resolution technique developed in their lab single-molecule footprinting. This method allowed them to simultaneously measure DNA methylation, accessibility, and transcription factor binding, at the level of single DNA molecules. They applied this across the whole genome in multiple cell types, including mouse embryonic stem cells and differentiated cells. This combination of scale and resolution allowed the scientists to gain a deeper understanding of DNA methylations role in gene regulation in a living cell.

The team found that while the accessibility of ~97% of the enhancers they studied was insensitive to DNA methylation, about 3% required the absence of DNA methylation to get activated. At these sites, methylation reduced DNA accessibility and directly prevented the binding of transcription factors. The identity of these methylation-sensitive enhancers varied across cell types and stages.

The 3% of enhancers that seem to be regulated by DNA methylation are enriched for cell-type specific enhancers. We think they are connected to genes that are important for cellular identity, said Elisa Kreibich, PhD student in the Krebs group and first author of the study,now published inMolecular Cell.

By making our measurements at the level of single molecules, we can figure out the connections and interactions between the layers of gene regulation that exist in a cell, added Krebs. While DNA methylation has often been used as a marker for cellular processes, including those involved in cancer, our study shows where it is truly instructive, rather than simply indicative.

Reference: Kreibich E, Kleinendorst R, Barzaghi G, Kaspar S, Krebs AR. Single-molecule footprinting identifies context-dependent regulation of enhancers by DNA methylation. Molecular Cell. 2023. doi: 10.1016/j.molcel.2023.01.017.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See the article here:
Epigenetic Regulation Studied at the Single-Molecule Level - Technology Networks

On this date: Dolly the Sheep meets the world – ABC27

EDINBURGH, SCOTLAND (WHTM) It was an achievement that many scientists believed was impossible. On Feb. 22, 1997, a scientific team headed by Professor Ian Wilmut at the Roslin Institute, part of the University of Edinburgh, introduced Dolly the Cloned Sheep to the world.

The misconceptions, misconstruals, misinterpretations, misapprehensions, and misoneisms started almost immediately.

A lot of people thought Dolly was the first animal to be cloned, ever. In fact, the first successful clonings, of frogs and fish, were done in the 1950s and 1960s. And as the Rosling Institute explains on its website, Dolly was not even the first cloned mammal.

That honour belongs to another sheep which was cloned from an embryo cell and born in 1984 in Cambridge, UK. Two other sheep, Megan, and Morag, had also been cloned from embryonic cells grown in the lab at The Roslin Institute in 1995 and six other sheep, cloned from embryonic and fetal cells, were born at Roslin at the same time as Dolly.

So what was it about Dollys birth that caused such excitement? She was the first mammal cloned from an adult cell. The process, called Somatic Cell Nuclear Transfer, starts by removing the genetic material from an egg cell, then replacing it with the genetic material from a different animal.

Dolly was cloned using genetic material from a mammary gland cell of a six-year-old Finn Dorset sheep, implanted into an egg cell from a Scottish Blackface sheep. Another Scottish Blackface served as her surrogate mother. When she was born on July 5, 1996, Dollys had the white face of a Finn Dorset, rather than the black face of her surrogate mother, proof she was indeed a clone. Because Dollys DNA came from a mammary gland cell, the research team named her after Dolly Parton. Science humor

The big breakthrough within the big breakthrough was that they did this with a specialized cell. An embryo starts out as a single cell. As the cell divides, and the embryo starts to grow, the cells start to differentiate, becoming, heart cells. liver cells, lung cells, brain cells, mammary gland cells-cells that specialize to perform a specific purpose. Dolly proved it was possible to reset the clock and make an adult cell act like a newly fertilized embryo.

The implication was that it would be possible to take a cell culture from, say, a prize cow, chicken, or sheep, and produce dozens, hundreds, thousands, or even millions of precise duplicates.

The other implication was that you could use human cells to create a clone army.

The pro and con arguments about cloning continue to this day, even though the type of cloning used to create Dolly has pretty well fallen by the wayside. As it turned out, Somatic Cell Nuclear Transfer had a low success rate. Dolly was the only animal born out of 277 cloned embryos, and years of research failed to improve the percentage of viable clones. And in the meantime, a better method was developed- Induced Pluripotent Stem Cells, or iPSC.

The technology of iPSC was developed by Japanese scientists Shinya Yamanaka and Kazutoshi Takahashi. In the early 2000s, they discovered by taking an adult cell and adding a few special genes, the cell would revert to an unspecialized form-a stem cell. The discovery has revolutionized genetic research while avoiding some of the ethical quandaries of SCNT cloning.

Stay up to date on the latest from abc27 News on-air and on the go with thefree abc27 Mobile app.

As for Dolly herself, she continued living a normal sheepish life at the Roslin Institute. She had six lambs with a Welsh Mountain ram called David; Bonnie 1998, twins Sally and Rosie in 1999, and triplets Lucy, Darcy and Cotton in 2000.

Soon after giving birth to the triplets, The institute suffered an outbreak of a virus called Jaagsiekte sheep retrovirus (JSRV), which causes lung cancer in sheep. Dolly was one of those infected. In February 2003, Dolly developed a cough, and a CT scan showed tumors in her lungs. Rather than allow her to suffer, the Institute put Dolly to sleep onFeb. 14, 2003, at the age of six.

Six years old is about half the usual lifespan of a sheep. When Dolly was a year old, the team at the Institute ran an analysis of her DNA and discovered her telomeres, the caps found at the end of chromosomes, were shorter than they should be for sheep of that age. Telomeres protect the DNA in chromosomes from damage, and get shorter as an organism ages. When Dolly died, it was widely presumed her short telomeres were (a) a result of cloning, and (b) at least partly responsible for her early demise-in effect, she was older than her years.

However, as the Roslin Institute website reports, extensive health screens on Dolly at the time did not find any conditions which could be directly related to premature or accelerated aging. And studies of cloned animals have found shorter, longer, and normal telomeres. So its hard to prove Dollys early death was directly related to cloning.

Since 2003, Dolly has been on display at the National Museum of Scotland in Edinburgh. Twenty years later, shes still one of their most popular exhibits.

For a list of animals that have been cloned, click here.

Read the original here:
On this date: Dolly the Sheep meets the world - ABC27

"Cell Therapy Market to Surpass $7,754.89 Million, by 2027, Fueled by Growing Investments in Research and Deve – openPR

, $7,754.89 2019, $48,115.40 2027, 25.6% 2020 2027. Cell therapy is a technology that relies on replacing diseased or dysfunctional cells with healthy functioning ones. Cells mainly used for such advanced therapies are stem cells, owing to their ability to differentiate into specific cells required for repairing damaged or defective tissues or cells.

Cell therapy is being increasingly used in the development of regenerative medicine, which involves the repair, replacement or regeneration of cells, tissues or organs that are damaged or diseased. Regenerative medicine is a multidisciplinary field that uses a combination of approaches, including stem cell therapy, tissue engineering, and gene therapy.

https://www.alliedmarketresearch.com/request-sample/5330

There are various types of cells that are used in cell therapy procedures, including blood and bone marrow cells, mature and immature tissue cells, adult stem cells, and embryonic stem cells. Transplanted cells such as induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), neural stem cells (NSCs), and mesenchymal stem cells (MSCs) are classified into two main groups, autologous cell therapy and non-autologous cell therapy.

Autologous cell therapy involves using a patient's own cells, which are collected, processed, and then re-administered back to the patient. Non-autologous cell therapy involves using cells from a donor, which are collected, processed, and then administered to the patient. The choice of autologous or non-autologous cell therapy depends on various factors, including the type of disease or condition being treated, the availability of suitable donor cells, and the patient's individual needs and preferences.

COVID-19 pandemic has had a significant impact on the cell therapy market. The widespread adoption of lockdown measures in many countries has led to a reduction in the number of clinics that are able to undertake new cases of stem cell therapy, organ transplant, and other treatments. This has resulted in a slowdown in the development and commercialization of new cell therapies.

In addition, many biopharmaceutical companies, including major players such as Pfizer and Eli Lilly, have announced clinical trial delays due to the pandemic. This has led to a delay in the approval and launch of new cell therapies, which has further contributed to the slowdown in the market.

The impact on allogeneic cell therapies, which are derived from a healthy donor, is particularly acute, as the pandemic has led to a shortage of donor cells and a disruption in the supply chain for these therapies. This has led to a delay in the development and commercialization of allogeneic cell therapies, which has further contributed to the slowdown in the market.

Financing and investments have played a significant role in driving the growth of the cell therapy market, and this trend is expected to continue in the coming years. The development of new companies in the industry is expected to boost organic revenue growth, as these companies bring innovative technologies and therapies to the market.

One example of such investment is Bayer's investment of $215 million in July 2019 for the launch of Century Therapeutics, a U.S.-based biotechnology start-up focused on developing therapies for solid tumors and blood cancer. This investment was aimed at supporting the development of new cell therapies and providing funding for clinical trials. Later, additional funding of $35 million from Versant Ventures and Fujifilm Cellular Dynamics was added to the financing, which is expected to further boost the market growth.

This kind of investment in the industry is expected to drive the development of new and innovative cell therapies, which will lead to increased adoption of these therapies in the treatment of various diseases and medical conditions. It is anticipated that the market will continue to attract significant investments and financing in the coming years, which will further accelerate the growth of the cell therapy market.

:https://www.alliedmarketresearch.com/purchase-enquiry/5330

1.By Cell Type: This refers to the type of cells used in the therapy. The different types of cells include stem cells (such as bone marrow, blood, umbilical cord-derived, adipose-derived stem cells, placenta, and nonspecific cells) and non-stem cells.

2.By Therapy Type: This refers to whether the therapy is autologous (using the patient's own cells) or allogeneic (using cells from a donor).

3.By Therapeutic Area: This refers to the medical conditions that the therapy is used to treat. Examples of therapeutic areas include malignancies, musculoskeletal disorders, autoimmune disorders, dermatology, and others.

4.By End User: This refers to the type of institution or organization that uses the therapy. The main end users are hospitals and clinics, and academic and research institutes.

5.By Region: This refers to the geographic regions where the therapy is used or sold. The main regions are North America, Europe, Asia-Pacific, and LAMEA (Latin America, Middle East, and Africa).

1.ALLOSOURCE2.CELLS FOR CELLS3.HOLOSTEM TERAPIE AVANZATE SRL4.JCR PHARMACEUTICALS CO.5.KOLON TISSUEGENE6.MEDIPOST CO.7.MESOBLAST LTD8.NUVASIVE9.OSIRIS THERAPEUTICS10.STEMEDICA CELL TECHNOLOGIES

?1.What is cell therapy, and how does it work?

2.What are the different types of cells used in cell therapy, and what medical conditions can they treat?

3.What are the main applications of cell therapy in modern medicine?

4.What is the current size of the cell therapy market, and what is the expected growth rate in the coming years?

5.What are the main drivers of growth in the cell therapy market, and what are the main challenges facing the industry?

6.What are the regulatory requirements for the development and approval of cell therapies, and how do they vary by region?

7.What are the main companies involved in the development and commercialization of cell therapies, and what are their competitive strategies?

8.What are the main trends and innovations in cell therapy research and development?

9.How do autologous and allogeneic cell therapies differ, and what are the advantages and disadvantages of each approach?

10.What are the main end-users of cell therapy products and services, and how do their needs and preferences shape the market?

https://www.alliedmarketresearch.com/checkout-final/435ed417be65921756bfb923bfd57c8a

:

pharmacogenomics markethttps://www.alliedmarketresearch.com/pharmacogenomics-market

Artificial Intelligence for Drug Discovery and Development Markethttps://www.alliedmarketresearch.com/artificial-intelligence-for-drug-development-and-discovery-market

Laboratory Equipment and Disposables Markethttps://www.alliedmarketresearch.com/laboratory-equipment-and-disposables-market

Ophthalmic Viscoelastic Devices (OVD) Markethttps://www.alliedmarketresearch.com/ovd-market

Menstrual Cup Market https://www.alliedmarketresearch.com/menstrual-cup-market

General Anesthesia Drugs Markethttps://www.alliedmarketresearch.com/general-anesthesia-drugs-market

Mobile Gamma Cameras Markethttps://www.alliedmarketresearch.com/mobile-gamma-cameras-market

Immunosuppressants Markethttps://www.alliedmarketresearch.com/immunosuppressants-market

Hybrid Operating Room Markethttps://www.alliedmarketresearch.com/hybrid-operating-room-market

Contact:

David Correa5933 NE Win Sivers Drive#205, Portland, OR 97220United StatesUSA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022UK: +44-845-528-1300Hong Kong: +852-301-84916India (Pune): +91-20-66346060Fax: +1(855)550-5975help@alliedmarketresearch.comWeb: https://www.alliedmarketresearch.com

About Us -

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.

Read this article:
"Cell Therapy Market to Surpass $7,754.89 Million, by 2027, Fueled by Growing Investments in Research and Deve - openPR

UC researchers developing method to repair hearts – EurekAlert

The regeneration and repair of cells that have been damaged in heart attacks could be possible in the future thanks to research at the University of Cincinnati.

When a person suffers a heart attack, also called a myocardial infarction, millions of heart muscle cells are starved of oxygen and die. Once the cells in the heart die, theres no natural system in the human body to replace them.

Yigang Wang, MD, director of the regenerative medicine division in UC's College of Medicine, is leading the development of a technique using something called a cell patch that could regenerate cells following a heart attack.

A cell patch is a lab-grown patch of muscle that would be affixed to the damaged area of the heart following a heart attack. The patch would replace the damaged cells and allow the heart to repair itself.

The problem with the current paradigm is that theres really not much that they can do except treat your symptoms, said Christian Paul, a research assistant in Wangs lab. Treating your symptoms isnt going to repair anything.

Within the heart are cells called cardiomyocytes, which are responsible for the beating and contraction of the heart. During a heart attack, those cells can be starved of oxygen and die.

When cardiomyocytes die, they lose their ability to contract and pump blood.

After a heart attack, those original cells are lost or become fibroblasts, Wang said. Then we could convert them to the original cells. That would be ideal to repair a myocardial infarction.

Wangs research is in the early stages, having done experiments in cell dishes and small animal models that have shown promise. In the future, breakthroughs that have been developed in the lab could help people avoid open heart surgery and receive better care.

If humans could regenerate the scarred area of the damaged heart into viable heart cells, less invasive procedures would be needed.

Our method, if in the future it could be used in the clinic, would be revolutionary, Wang said.

The cell patch, which Wang likened to a sandwich with multiple layers of cells, would include cardiomyocytes, fibroblasts, smooth cells and endothelial cells.

Fibroblasts are cells that contribute to the formation of connective tissue. They support the cells around them but cant pump blood.

Endothelial and smooth cells form new blood vessels, delivering nutrients to the damaged tissue, and remove waste. While the researchers at UC and worldwide have worked to develop cell patches, and been hopeful of their potential, there have been impediments to making cell patches a viable treatment.

Many cells, whether you inject them or put a cell patch on it, after a week, 98% of the cells die, Wang said.

To overcome these challenges, the UC researchers have developed new techniques and products.

To create new cardiomyocytes, the researchers use stem cells that are derived from skin or blood cells and reprogrammed into an embryonic-like state that allows the development of any type of human cell needed. The UC researchers have developed ways to make the cells mature quicker.

Wang and his team used CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology a genome editing system to alter genes.

By activating reprogramming genes in the body, their new approach turns heart scar tissue into cardiomyocytes. Also, by inhibiting a certain gene, these cells can continue to multiply, and the damaged cells can rejuvenate.

Additionally, they created a new hydrogel. The hydrogel, which Paul compared to a glue, attaches the cell patch to the heart.

The hydrogel developed at UC would introduce oxygen and growth factors, creating the best possible environment for cells to develop.

The UC team has patented its new products and techniques with the help of the staff at UCs Tech Transfer team at the 1819 Innovation Hub, which has given them more time to focus on their work.

Theyve been awesome, Paul said. Most of the paperwork and administrative aspects, theyve taken care of, and theyve asked us for the basic information and taken it from there.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See more here:
UC researchers developing method to repair hearts - EurekAlert

At OurCrowd Summit, Startup Has High Hopes for COVID-busting … – The Media Line

Leading MedTech and FoodTech startups converge on international investors summit in Jerusalem, as buyers and sellers come together to check out latest technological innovations

After its pandemic success, Israeli-Canadian startup SaNOtize is hoping that clinical trials will show that its pioneering antiviral nasal spray can be used to treat the flu and other upper respiratory viruses.

The nitric oxide spray, called Enovid, has been proven to effectively prevent, treat and shorten the course of a COVID-19 infection.

Nitric oxide kills bacteria, viruses, fungi and we have a way to deliver it, Dr. Gilly Regev, CEO and co-founder of SaNOtize, told The Media Line. Instead of pressurized gas cylinders we deliver it in liquids. You can deliver it at the right dose and at the right place to get rid of bacteria, viruses and fungi.

A report published in the prestigious British peer-reviewed The Lancet medical journal last year showed that when used six times daily over a one-week period, the spay effectively reduced SARS-CoV-2 RNA in the nasal cavity by roughly 94 percent in 24 hours, and 99% in 48 hours. The study was carried out in clinical sites across India during the delta and omicron surges.

Weve done some clinical trials, double-blind placebo trials treating people who already have very high viral loads and we showed that we can reduce the viral load significantly, Regev affirmed, adding that the nitric oxide led to those infected with COVID recovering twice as fast as control groups.

Enovid has already been approved and is for sale in dozens of countries around the world, and now SaNOtize has its eyes set on combating yet another widespread virus: influenza.

What were going to do next is do clinical trials with flu, Regev said.

Regev spoke to The Media Line on the sidelines of the 2023 OurCrowd Global Investor summit, which took place in Jerusalem last week. The summitIsraels largest investor eventsaw more than 9,000 people from around the world take part in lectures, briefing, networking sessions and startup exhibitions on a wide variety of tech-related topics.

Among the many MedTech startups making waves at the event was Binah.ai, which has developed an artificial intelligence-based platform that detects vital signs using a cell phone camera.

The platformwhich is about to receive FDA approvalcan read a persons heart rate, blood pressure and even hemoglobin levels by simply scanning their face.

We are working today with 11 out of the top 100 insurance companies in the world, including Sompo from Japan, Generali in Germany, MetLife in Malaysia and quite a few other countries, David Maman, CEO and founder of the startup, told The Media Line.

In terms of accuracy, Maman said that everything is aligned to be medically approved, which means that they meet the requirements for an FDA submission.

FoodTech was another significant arena featured at the summit.

Mermade Seafoods, for instance, has found a way to cultivate scallops using fewer resources than traditional aquaculture. The company is hoping to disrupt the $8 billion global scallops market with its technology.

We cultivate cells, basically taking embryonic stem cells and cultivating them, said Daniel Einhorn, CEO and co-founder of the startup.

Other FoodTech innovators were looking at ways to make popular foods healthier.

Blue Tree Technologies has developed a method to remove sugar from natural fruit juices using a patented technology that extracts disaccharides from liquids.

The technology is based on a procedure in which we filter the juice and then the juice runs through a column with a special mineral that acts like a magnet, Michael Gordon, CEO of Blue Tree Technologies, told The Media Line. The magnet is taking the disaccharide from the beverage itself.

The amount of sugar removed depends upon a clients needs, he added. Blue Tree has partnered with leading Israeli juice manufacturer Priniv and its products are set to hit supermarket shelves in the country by the end of year.

When you remove sugar from beverages then manufacturers pay less taxes so everyone wins, Gordon said.

Whether it is antiviral treatments, AI-based healthcare or reducing peoples sugar intake, the OurCrowd summit brought together some of the worlds leading entrepreneurs and tech experts, many of whom have come up with visionary solutions to some of humanitys most pressing problems.

Here is the original post:
At OurCrowd Summit, Startup Has High Hopes for COVID-busting ... - The Media Line

"Cell Therapy Market to Expand Rapidly, Expected to Reach $ 48,115.40 million by 2027, According to Report on – openPR

Cell Therapy Market size, share

It's interesting to note the various types of cells used in cell therapy procedures, including blood and bone marrow cells, mature, immature & solid tissue cells, adult stem cells, and embryonic stem cells. The use of induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), neural stem cells (NSCs), and mesenchymal stem cells (MSCs) for transplantation is also noteworthy.

:https://www.alliedmarketresearch.com/request-sample/5330

The application of cell therapy in regenerative medicine is a multidisciplinary area aimed at maintaining, improving, or restoring cell, tissue, or organ function using methods mainly related to cell therapy. The differentiation between autologous cell therapy and non-autologous cell therapy is also important, as it relates to whether the transplanted cells are from the same individual or from a donor. All of these factors are important to consider in the ongoing development and growth of the cell therapy market.

It's unfortunate to hear that the cell therapy market has been negatively impacted by the pandemic. The temporary halting of stem cell therapy and other treatments due to the pandemic-related lockdowns may have significant implications for patients, especially those in need of urgent or life-saving treatments. The delays in clinical trials by biopharmaceutical companies may also have an impact on the development of new cell therapies.

The impact on allogeneic cell therapies or cell therapies derived from a healthy donor is particularly concerning, as these therapies require a supply of healthy donor cells, which may be impacted by the pandemic. It will be important to monitor how the cell therapy market recovers from the pandemic and how the industry adapts to new challenges and changes in the healthcare landscape.

The implementation of effective guidelines for cell therapy manufacturing, as well as the development of advanced genomic analysis techniques, are likely to drive the growth of the market. The vast number of researches being conducted by cancer societies is also a positive development, as it may lead to new cell therapy treatments for cancer and other diseases.

The proven effectiveness of transplants is an important factor as well, as it demonstrates the potential benefits of cell therapy. The transplantation statistics for 2019 in the U.S. provide an indication of the demand for these treatments and the potential impact they can have on patients.

It's also interesting to note that the Asia-Pacific region has high potential for growth in the cell therapy market due to its large population, which can serve as a potential patient base. The growth of healthcare infrastructure and the increase in affordability in developing countries such as India and China is also expected to contribute to the growth of the cell therapy market in these regions. It will be important to monitor how these factors continue to impact the market in the coming years.

-19? :https://www.alliedmarketresearch.com/connect-to-analyst/5330

, , , , -, . ' :

By Cell Type:Stem CellBone MarrowBloodUmbilical Cord-DerivedAdipose-Derived Stem CellOthers (placenta, and nonspecific cells)Non-stem CellBy Therapy Type:AutologousAllogeneicBy Therapeutic Area:MalignanciesMusculoskeletal DisordersAutoimmune DisordersDermatologyOthersBy End User:Hospitals & ClinicsAcademic & Research InstitutesBy Region:North America (U.S., Canada, Mexico)Europe (UK, Germany, France, Spain, Italy, Rest of Europe)Asia-Pacific (Japan, India, China, Australia, Rest of Asia-Pacific)LAMEA (Brazil, Saudi Arabia, South Africa, Rest of LAMEA

(2022-2030) :https://www.alliedmarketresearch.com/checkout-final/9363e18fa61d10c764bf10f984388c1e

https://www.alliedmarketresearch.com/Breast-Biopsy-market

https://www.alliedmarketresearch.com/external-defibrillators-market

https://www.alliedmarketresearch.com/prosthetic-heart-valve-market

https://www.alliedmarketresearch.com/blood-market

https://www.alliedmarketresearch.com/insomnia-market

https://www.alliedmarketresearch.com/intraoral-scanners-market

https://www.alliedmarketresearch.com/pneumonia-testing-market

https://www.alliedmarketresearch.com/ulcerative-colitis-market

About Us -

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa5933 NE Win Sivers Drive#205, Portland, OR 97220United StatesUSA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022UK: +44-845-528-1300Hong Kong: +852-301-84916India (Pune): +91-20-66346060Fax: +1(855)550-5975help@alliedmarketresearch.comWeb: https://www.alliedmarketresearch.com

This release was published on openPR.

See the rest here:
"Cell Therapy Market to Expand Rapidly, Expected to Reach $ 48,115.40 million by 2027, According to Report on - openPR

10 Fascinating Early Experiments in Cryogenics – Listverse

If asked about cryogenics, a few things might come to mind. No, that urban legend about Walt Disney being cryogenically frozen is not true. You might also think about the equally fanciful Planet of the Apes, Demolition Man, or Futurama.

Cryogenics (from the Greek words for cold and to generate) refers to the creation of temperatures below what humans normally experience. Besides looking at ways to produce and maintain cold temperatures, cryogenics also involves studying the freezing of materials at cryogenic temperatures. Over the last two centuries, the field of cryogenics has advanced substantially.

So lets take a closer look at ten early experiments in cryogenics.

Related: Top10 Absurd Scientific Experiments And Discoveries

Born in 1797, James Arnott was an English doctor who focused on cryotherapy. Before moving to London, the doctor worked as the senior physician at Englands Brighton Infirmary. Arnott was even the first to utilize extreme cold to destroy tissues. In 1819, Arnott used cryotherapy to freeze breast and uterine tumors while treating cancer patients.

Arnott mixed two parts ice and one part chloride of sodium to make temperatures between -0.4 and -11.2F (-18 and -24C). To perform experiments, Arnott even created his own equipment, which included a waterproof cushion, two flexible tubes to carry water from the impacted area, a reservoir for the mixture, and a sump (a basin to hold wastewater). Arnott performed the first cryosurgery in 1845. Arnott acknowledged the potential cryotherapy had for treating cancer as well as anesthetizing skin before surgery. Today, cryotherapy is still used to treat various types of cancer.[1]

In December 1877, within days of one another, Louis Paul Cailletet (as well as Raoul Pictet) arrived independently at methods to liquefy oxygen.

Cailletet was educated at Lycee Henri IV in Paris and was later employed at his fathers ironworks, where he worked on his studies. In 1869, Cailletet began to experiment with high-pressure chemistry. In December 1877, Pictet announced to the French Academy that he had liquefied oxygen. Two days after Pictet, Cailletet announced he had made the same discovery.

Both men acknowledged that cooling and compression were required to liquefy oxygen but utilized different techniques to do so. Cailletet achieved the liquefaction of gasses through the use of a compression apparatus. Pictet utilized the cascade method, which involved evaporating liquid sulfur dioxide, which turned carbon dioxide into a liquid. Instead of Cailletets method, this produced liquid gas in larger amounts, and its technique could be easier applied to other types of gas. Today, liquid hydrogen and helium play a critical role in cryogenics.[]

Born in Atlantic City in 1922, Irving S. Cooper later received a medical doctorate from the University. He helped to organize the St. Barnabas Hospital Neurosurgery Department in New York City in the 1950s and 1960s. During his employment at St. Barnabas, Cooper became known for performing thousands of operations to help people with movement disorders.

Cooper had a habit of videotaping his patients surgeries. On December 25, 1961, Cooper received a wine bottle opener that lifted corks from bottles by injecting carbon dioxide. What fascinated Cooper was how a portion of the gadget cooled a section of the bottle. Cooper ended up utilizing this bottle-opening technology in surgery.

Patient confidentiality was not what it is today during the 1960s. Consequently, many current experts view Coopers experiments as controversial due to their confidentiality and boundary-pushing nature. Despite these concerns, Cooper created cryosurgery, which involves utilizing liquid gasses to remove diseased tissue.[3]

Wilma Jean McLaughlin almost became the first person cryogenically frozen in 1965 by The Life Extension Society, an organization that offered to freeze a person free of charge at its short-term freezing facility. On May 20, 1965, McLaughlin passed away from heart and circulatory issues. A group of cryogenic scientists attempted to freeze Mclaughlin, but the process failed. Additionally, Juno Incorporated, the company that allegedly supplied the capsule to store McLaughlins body, reported that the device was still being tested and that only a prototype existed.

The experiment that would have seen the freezing of McLaughlin was abandoned. Reports about what exactly prevented McLaughlin from becoming frozen are conflicted. Some reasons cited for why the experiment did not continue include disagreement among McLaughlins relatives and minister about the experiment, the local doctor not helping with the experiment, the hospital administration refusing to help with the experiment, the cryogenic capsule not being prepared, and the minister warning that laws were not in place. At the time of her death, the woman was also not aware that her husband wanted to freeze her.

While technically a failed experiment, McLaughlins situation pushed the Life Extension Society to perform its first cryo-freezing of a human being shortly after.[4]

In the early 1960s, the Cryo-Care Equipment Corporation in Arizona was the only company that did actual cryogenic freezings by utilizing liquid nitrogen. In 1966, the first human body was frozen after having been embalmed for two months.

The process was done by placing the middle-aged womans corpse in liquid nitrogen. The woman was then stored at an above-freezing temperature in a mortuarys refrigerator. The late woman, who was from Los Angeles, was later thawed out a year later and buried by her loved ones.

The same year, the freezing of a San Francisco school teacher was similarly aborted because the man was dead for too long. Researchers decided that even if his brain could later be revived someday, it was damaged beyond repair. [5]

A former University of California-Berkeley professor who passed away from renal cancer in 1967, Bedford was the first human to be cryogenically frozen and stored in the hopes that one day he will be revived.

Bedford used his own money and left $100,000 for cryogenic research when he passed away. Bedfords surviving loved ones ended up spending more than this to defend his will and freezing against other relatives. His body was preserved by several doctors, who injected Bedfords body with a solution of 15% dimethyl sulfoxide and 85% ringers solution. Bedfords brain was likely not protected from these chemicals.

Until 1969, Bedford was stored at Edward Hopes Crypto-Care facility in Phoenix, Arizona. In addition to being a pioneer in cryogenics, Hope was also a wigmaker who kept Bedfords de-animated body in liquid nitrogen. Since 1982, Bedfords corpse has been located at the Alcor Life Extension Foundation in Scottsdale, Arizona. In 1994, concerns about earthquakes, as well as regulatory issues, required Bedford and all 33 frozen corpses where he was stored to be moved to Arizona again. January 12th, the date that Bedford was cryopreserved, is still known as Bedford Day by those in the cryogenics field. [6]

Peter Mazur was a U.S. researcher who created new ways to preserve biological material through crypto preservation, which ultimately allows scientists to store or study biological material over an extended period. Mazurs research during the 1960s and 1970s also led to various discoveries revealing elements that can damage cells during cryopreservation.

Born in New York City in 1928 to a housewife and business writer who lectured at Harvard, Mazur graduated from Harvard University and began experimenting with preserving fungus spores through dehydration. In his landmark paper, A Two-Factor Hypothesis of Freezing Injury: Evidence from Chinese Hamster Tissue-Culture Cells, Mazur found that cell exposure to high salt concentration and ice formation within the cell can lead to cellular damage.

Mazurs work is influential because he determined the optimum cooling rate for each type of cell that is slow enough to prevent freezing but rapid enough to minimize exposure to high salt concentration. Mazurs studies also helped to form the basis for significant advances in cryobiology and cryopreservation.[7]

The Cryonics Society of New York began freezing patients in the late 1960s. Relatives of the subjects paid for the cryo suspensions, while the organization was required to supply storage capsules. In 1972, the company froze its first child, which the Cryonics Society of New York was pleased about due to the publicity associated with the act

In 1972, Genevieve de la Poterie from Montreal became the first cryogenically frozen child. De La Poterie, the daughter of a pharmaceutical salesman and an opera singer, passed away from kidney cancer on January 25, 1972, at eight years old, at Saint Justines Hospital. The California-based Life Extension Foundation was supposed to freeze the childs body. The organization did not do this properly, and the childs body ended up worse off without a chance of being brought back to life. The body was then frozen by the Cryonics Society of New York.

The childs body was stored by the Cryonics Society of California until 1994 when the Chatsworth Disaster occurred. This event saw the failure of the vacuum pump at the location where Nelson kept the bodies. This led to the destruction of many de-animated bodies.[8]

The first human embryo was cryopreserved in 1983. Since this point, cryopreservation of human blood, stem cells, embryos, sperm cells, and oocytes have been involved in over 300,000 births. This initial cryopreservation was performed by a medical research team at Monash University. It was was tasked with reporting on various methods that could be utilized to achieve human pregnancy through in vitro fertilization (IVF) and the freezing of embryos before womb replacement.

In 1971, the program started the research that still underpins IVF today. The study included collecting eggs for research from women volunteers in Melbourne, Australia. In 1973, medical workers in the program achieved the first signs that IVF could be successful in treating infertility issues. In 1938, the Monash team performed another IVF experiment that involved a donated egg cell. Even though this pregnancy ultimately ended in miscarriage at 10 weeks, this experiment served as the basis for additional IVF experiments. Also, in 1983, the program achieved the first IVF births using frozen embryos. This experiment presented evidence that embryos frozen for a time could later be planted into a uterus and turned into a fetus.

In vitro fertilization has gone on to become a treatment method for both men and women who are experiencing infertility. IVF involves the fertilization of an egg cell outside a females body. Medical workers then inseminate the egg with sperm and implant the fertilized egg into the womans uterus. Additionally, Monash IVF is now recognized as one of Australias leaders in fertility programs.[9]

In 1983, Miles, a beagle, participated in a cryonics experiment at the University of California Berkeley. Named after the character that Woody Allen played in Sleeper, the dog had his blood substituted with a glycerol solution. The dog was then cooled to a few degrees above freezing. After spending fifteen minutes in suspended animation, the dog was revived. The researchers later presented details to a meeting of the Federation of American Societies for Experimental Biology in Washington.

Following the experiment, cryonics companies in the United States reported a large increase in the number of inquiries. At the time, scientists hailed this as a substantial step forward in cryogenics.

The Los Angeles Times later published an article clarifying that the dog was not placed at a temperature as low as the freezing level for humans who are cryogenically suspended. The article also noted that the researcher who performed the study was not exactly a Berkeley medical researcher.[10]

Follow this link:
10 Fascinating Early Experiments in Cryogenics - Listverse

The Rise of Biotech Startups: Advancing Science and Medicine … – Lexology

The COVID-19 pandemic has had a major impact on various industries globally, but the biotech industry has proven to be resilient. Initially, the pandemic caused a setback in the growth and financial stability of the biotech industry, but as the need for scientific breakthroughs, particularly in combating the virus, became more apparent, the biotechnology industry started to recover.

According to a study conducted by McKinsey, venture capitalist (VC) companies increased their investments in biotech startups from 2,200 globally in 2016 to 3,100 by 2021. This highlights the growing importance of investing in science, especially in the biotech industry.

Biotechnology has a wide range of applications that impact our daily lives in many ways. It plays a crucial role in developing food products, using genetically modified organisms, finding sustainable ways of procuring resources, and managing waste. It has the potential to improve our health and that of the planet.

Modern biotechnology has led to several breakthrough products and technologies that aim to reduce our environmental footprint, increase energy efficiency, and promote the use of cleaner energy. It has also contributed to feeding the hungry and enhancing industrial manufacturing processes.

The Biotechnology Revolution

The biotechnology industry has seen remarkable growth and progress over the past few years, with numerous startups making a big impact in different areas of the field. Here are some of the startups that have revolutionized the biotechnology industry:

Cell TherapyCellarity is a startup that has made a significant impact in drug discovery. Their approach involves targeting cell behavior rather than individual proteins. This approach to medicine is based on the understanding of how a disease impacts cell behavior rather than traditional methods of targeting the illness.

NeurologyBionaut Labs is a startup that has revolutionized the treatment of brain disorders through precision-targeted medicine. Their medical method involves the use of remote-controlled micro-robots, known as Bionauts, which have the potential to change the way central nervous system disorders are treated.

Tissue RegenerationEndogena Therapeutics is a clinical-stage biotech company that works on discovering and developing first-in-class endogenous regenerative medicines. Their goal is to repair and regenerate tissues and organs and treat degenerative conditions related to aging and genetic disorders.

Cellular BiologyGinkgo Bioworks believes that biology is the most advanced manufacturing technology on the planet. They aim to program cells to make everything from food to materials to medicine. Their research focuses on modifying microorganisms and they work with several partner companies to develop microbes for different purposes.

Genetic MedicinesPassage Bio is a startup that aims to transform the future through the power of gene therapy. Their R&D model focuses on changing the lives of patients with central nervous system disorders and their goal is to develop a portfolio of five life-transforming AAV-delivered therapeutics.

Gene TherapyKriya Therapeutics is a startup that is revolutionizing the process of how gene therapies are designed, developed, and manufactured. They aim to improve speed to market and reduce costs. Their research targets a wide range of diseases, including obesity and diabetes. Their strong commitment to reducing cost per dose and bringing their products to market faster sets them apart from their competitors.

Tissue RegenerationBiosplices mission is to restore health through first-in-class therapies that harness alternative splicing. The startup is studying ways to manipulate stem cells in order to prevent conditions such as skin diseases, bone and joint ailments, and even hair loss. They are investigating ways to make cells of aging people regenerate as fast as developing embryos do.

Artificial Intelligence in Drug DiscoveryAtomwise is a startup that utilizes artificial intelligence to revolutionize drug discovery. They use deep learning algorithms to analyze large datasets, allowing them to discover new drug candidates faster and more accurately than traditional methods.

Personalized Cancer TherapyNatera is a leading provider of cancer genomics and personalized medicine. Their technology helps to analyze cancer genomic information and personalize patient treatment accordingly. This has the potential to greatly improve patient outcomes and reduce the risk of side effects.

BioprintingOrganovo is a bioprinting company that creates functional human tissues for medical research and therapeutic applications. Their technology has the potential to revolutionize the way we approach disease and injury, as well as reduce the need for animal testing.

Precision AgricultureThe Climate Corporation is a subsidiary of Monsanto that provides farmers with customized data analysis to improve their crop yield and reduce waste. Their technology takes into account a variety of factors, including weather patterns and soil analysis, to provide farmers with the information they need to make informed decisions.

Synthetic BiologyAmyris is a synthetic biology company that uses engineered yeast to produce a variety of compounds, including fuels, fragrances, and personal care products. Their technology is designed to reduce the impact of human activities on the environment, as well as to provide sustainable alternatives to traditional products.

BiomaterialsEcovative Design creates sustainable materials from mushroom roots and agricultural waste. Their materials are being used in a variety of applications, including insulation, furniture, and packaging, and have the potential to greatly reduce the amount of waste generated by traditional materials.

These are just a few examples of the startups that have been instrumental in revolutionizing the biotechnology industry. With continued investment and innovation, it's exciting to see what the future holds for this rapidly growing field.

The Future of Biotech Startups

The biotech industry has seen significant growth in recent years, with increased funding from venture capitalists, partnerships, and IPOs. The amount of venture capital invested in the biotech sector reached $36.6 billion in 2020, with the majority of investments happening in the US, followed by Europe and China. Joint partnerships and ventures reached a total of $170.6 billion in 2020, with a likely much larger undisclosed value.

One reason for the growth of the biotech industry is the increased accessibility and affordability of technology. This, combined with growing investment interest, points to a bright future for the industry.

In addition, the future of biotech startups is expected to be more founder-led. This means that the person who cares most about the research, the founder, will have more control over the direction of the biotech startup. This shift is evident in the recent successful IPOs of biotech startups like Recursion Pharmaceuticals, AbCellera, Ginkgo Bioworks, and SQZ Biotech, which are all led by their creative and scientific founders. This trend is being acknowledged by investors, who are increasingly supportive of companies led by their founders.

Conclusion

The pandemic may have temporarily slowed down the growth of the biotech industry, but the world now recognizes the need for more investment in the field. Biotech startups have made significant contributions to the advancement of science and medicine, bringing new innovations in cell therapy, micro-robotics, tissue regeneration, cellular biology, and genetic medicine.

As the biotech industry continues to grow, we can expect even more groundbreaking innovations in the field. With increased investment from venture capitalists and accessible technology, the future of the biotech industry looks bright. Furthermore, startups in this industry are more likely to be led by their founders, who are driven by a passion for their research and a desire to make a real impact.

Read the original here:
The Rise of Biotech Startups: Advancing Science and Medicine ... - Lexology

The Global Advanced Therapy Medicinal Products CDMO Market … – GlobeNewswire

New York, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Advanced Therapy Medicinal Products CDMO Market Size, Share & Industry Trends Analysis Report By Indication, By Product, By Phase, By Regional Outlook and Forecast, 2022 - 2028" - https://www.reportlinker.com/p06422807/?utm_source=GNW Advanced Therapy Medicinal Products (ATMPs) are advanced therapeutic medications that are focused on gene therapy or cell therapy.

CDMOs primarily support their clientele in the process of drug discovery through the provision of manufacturing capabilities and also help the pharmaceutical industry as a whole. The increase in the number of molecular drug approvals, the growing prevalence of infectious diseases, and the growing favorability for innovative therapeutics demand are inducing a rise in the number of CDMO setups in order to facilitate the quick development and production of therapies.

Because of this, the research, knowledge, and manufacturing capabilities of CDMOs are absolutely essential for moving the drug development process forward. Innovative treatments such as somatic cell therapy, gene therapy, and tissue-engineered products are all included in the category of advanced therapy medical products. It is expected that these therapies would deliver significant health advantages.

Medications derived through gene therapy contain genes that have been shown to have a curative, preventative, or diagnostic function. In most cases, they are used to treat a wide range of ailments, such as genetic disorders, cancer, or diseases that have a protracted course of treatment, and they function by introducing recombinant genes into the body. Additionally, a segment of DNA known as a recombinant gene is one that has been synthesized in the lab by combining strands of DNA derived from a variety of different sources.

COVID-19 Impact Analysis

Mesenchymal stem cells (MSCs), an ATMP, also offered a cutting-edge approach to treating the COVID-19 virus. Due to the challenging nature of the manufacturing process, the COVID-19 pandemic has had a substantial impact on the cell and gene therapy sector. Tissue engineering has significantly benefited from recent technology advancements. Damaged organs and tissues can be replaced or have their functionality restored with this technique. Similar to this, cell and gene therapy are attracting a lot of interest from patients in order to treat rare diseases, which are growing globally. Therefore, the pandemic affected the advanced therapy medicinal products CDMO market positively.

Market Growth Factors

Rising Need for CDMOS Due to Increasing Number of ATMP Clinical Trials

The growing number of clinical studies for advanced therapy medicinal products is one of the key factors driving the need for CDMOs. There were 3,579 gene, cell, and RNA therapies in development as of Q1 2022, according to a study by the American Society of Gene and Cell Therapy. According to the research, as of Q1 2021, the pipeline for gene cell therapy has grown by 16%. Genetically engineered cell therapies are being outperformed in the pipeline by CAR-T cell therapies. Furthermore, 98% of CAR-T cell treatments are still being developed for cancer-related indications. All these factors influence an increase in the number of CDMO and thus promote the growth of the advanced therapy medicinal products CDMO market.

Increasing efforts to develop novel therapies for various diseases

The effect of rising product demand around the world is a significant market trend that has prompted the development of novel therapeutic solutions. Over the course of the projection period, increasing product demand and significant increase in gene and cell therapies are anticipated to fuel growth opportunities for the market. CDMO assures the complete solution, starting with the planning of clinical trials and concluding with drug production. While CDMOs can prepare the drug, pharmaceutical and biopharmaceutical companies increase their research to develop innovative and efficient medicines. Therefore, each of these reasons contributes to the expansion of the advanced therapy medicinal products CDMO market.

Market Restraining Factors

Specific drawbacks of cell therapy methods of ATMP

Stem cell therapys primary limitation is that the cells of a single origin can only make cells of the same origin and type, for example, brain cells can only produce more brain cells. This is one of the procedures most significant downsides. The utilization of cell therapies would become more constrained as a result of these drawbacks. Since the use of stem cell therapy can result in the destruction of human embryos, one might expect to see a decline in the demand for these therapies. In addition, it is expected that the risk of contamination and the possibility of technological malfunctions may act as a barrier to the expansion of the automated cell therapy processing systems, which would hamper the growth of the advanced therapy medicinal products CDMO market.

Product Outlook

Based on product, the advanced therapy medicinal products CDMO market is segmented into gene therapy, cell therapy, tissue engineered and others. The cell therapy segment procured a considerable growth rate in the advanced therapy medicinal products CDMO market in 2021. New cell types are continuously being introduced to the domain of cellular therapies, which presents numerous chances for businesses to strengthen their market positions. The significant unmet need for cell therapy production, the recent approval of sophisticated medicines, and the demonstrated efficacy of these products are also drawing new players to the industry. These factors are therefore, propelling the expansion of the segment.

Phase Outlook

On the basis of phase, the advanced therapy medicinal products CDMO market is bifurcated into phase I, phase II, phase III, and phase IV. The phase I segment acquired the largest revenue share in the advanced therapy medicinal products CDMO market in 2021. The segments expansion can be attributed to rising R&D efforts and an increase in the number of advanced therapy human trials. Phase 1 assists in ensuring a drugs safety levels when it is given to a small group of patients in a variety of doses and dosing formats. The major goal of this phase is to ascertain the largest dose a patient may get without experiencing any negative effects.

Indication Outlook

By indication, the advanced therapy medicinal products CDMO market is fragmented into oncology, cardiology, central nervous system & musculoskeletal, infectious disease, dermatology, endocrine, metabolic, genetic, immunology & inflammation, ophthalmology, hematology, gastroenterology, and others. The oncology segment witnessed the maximum revenue share in the advanced therapy medicinal products CDMO market in 2021. The prevalence of the disease, the strategic actions made by key competitors, and the accessibility of cutting-edge medicines utilized to treat various cancer indications are all contributing factors to the segments rise. Oncology clinical trials include all phases of the process where Phase I trials determines dose and phase II analyses define efficacy in a single tumor type.

Regional Outlook

Region wise, the advanced therapy medicinal products CDMO market is analyzed across North America, Europe, Asia Pacific and LAMEA. The North America region recorded the highest revenue share in the advanced therapy medicinal products CDMO market in 2021. This can be due to rising interest in innovative therapies and rising outsourcing activities. The growing burden of diseases like cardiovascular, cancer, and certain rare genetic disorders have raised the levels of research and funding for the development of ATMPs that may serve as treatment methods for these diseases. It is projected that America will maintain its position as a leader in R&D for cutting-edge treatments in the coming years.

The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Thermo Fisher Scientific, Inc. (Patheon, Inc.) and Lonza Group AG are the forerunners in the Advanced Therapy Medicinal Products CDMO Market. Companies such as AGC Biologics, Inc., WuXi Advanced Therapies, and Catalent, Inc. are some of the key innovators in Advanced Therapy Medicinal Products CDMO Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc. (Patheon, Inc.), AGC Biologics, Inc. (AGC, Inc.), Catalent, Inc., Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation), WuXi AppTec Co., Ltd. (WuXi Advanced Therapies), Lonza Group AG, Celonic AG (JRS PHARMA GmbH & Co. KG), Rentschler Biopharma SE, and Bio Elpida (Polyplus-transfection SA.)

Recent Strategies Deployed in Advanced Therapy Medicinal Products CDMO Market

Acquisitions and Mergers:

Aug-2022: Catalent acquired Metrics Contract Services (Metrics), a US-based organization, primarily into providing contract development and manufacturing services for the medical sector. The acquisition advances Catalents ability to better serve its clients, particularly those clients with R & D pipelines having rare, orphan, diseases for oncology and other therapeutic areas.

Apr-2022: Catalent took over Erytechs cell Therapy Development and Manufacturing Facility in Princeton, New Jersey. The 30,900-square-foot manufacturing plants acquisition reflects Catalents devotion to fulfilling the growing demand for cell therapies.

Aug-2021: AGC Biologics acquired a commercial facility in Longmont, Colorado, USA from Novartis Gene Therapies. The acquisition expands AGCs manufacturing capacity supporting its global end-to-end Cell and Gene Therapy (C>) offerings and further expanding cell and gene therapy presence in the US.

Mar-2021: WuXi AppTec acquired OXGENE, a pioneering United Kingdom-based contract research, and development organization. Through this acquisition, the company aims to provide its customers with end-to-end aid in the development and creation of advanced cell and gene therapies.

Jul-2020: AGC took over MolMed, an Italy-based biotechnology company. The acquisition brings in MolMeds expertise and competence in development and GMP manufacturing services to AGC Biologics global CDMO service offerings.

Partnerships, Collaborations and Agreements:

Jan-2023: Catalent came into agreement with Sarepta Therapeutics, a US-based provider of precision genetic medicines. The commercial supply agreement involves Catalent manufacturing Sareptas gene therapy delandistrogene moxeparvovec (SRP-9001) meant for the treatment of Duchenne muscular dystrophy (DMD).

Aug-2022: AGC Biologics partnered with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs). The partnership involves cashing on RoosterBios media and cell products and AGCs gene and cell therapy manufacturing abilities, to develop an end-to-end solution for the production and expansion of exosome and hMSC therapeutics that help media and cell growth services.

Apr-2022: WuXi Advanced Therapies partnered with Bioprocessing Technology Institute, a Singapore-based research institute. The partnership involves accelerating cell and gene therapy products in the APAC region, and focuses on WuXi ATUs Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) technology that enhances adeno-associated virus (AAV) yields and particle quality.

Feb-2021: Rentschler Biopharma SE signed an agreement with Cell and Gene Therapy Catapult (CGT Catapult), an independent center of excellence in innovation advancing the UKs cell and gene therapy industry. The agreement involves leveraging Catapults expertise to set up a manufacturing capability in advanced therapy medicinal products intended for clinical trial supply at Catapults manufacturing facility in Stevenage, England.

Nov-2020: Lonza came into partnership with Be The Match BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies. Through this partnership, the company aims to offer end-to-end solutions that advance the growth of cell and gene therapies throughout the CGT supply chain.

Feb-2020: Catalent signed a contract with Zumutor Biologics, a US-based biotechnology company, primarily into providing NK cell therapeutics. The agreement involves manufacturing Zumutors ZM008 meant for solid tumor treatment.

Product Launches and Expansions:

May-2020: WuXi Advanced Therapies launched the CAR-T Cell Therapy Platform. A platform intended for advanced therapy companies providing them with various capabilities including, regulatory and technical expertise, full in-process and release testing, robust quality control, etc. The new platform advances the time taken for cell and gene therapy development, at the same time offering greater definiteness.

Jan-2020: WuXi Advanced Therapies unveiled the associated virus (AAV) Vector Suspension Platform. The platform supports advancing the timeline for cell and gene therapy development, at the same time offering greater predictability.

Geographical Expansions:

Oct-2022: Lonza expanded its laboratory space at its facilities in Houston (US) and Geleen (NL). The capacity expansion is intended to expand the CGT process and analytical development. Moreover, the expansion reinforces Lonzas global process development service offerings.

May-2022: AGC Biologics expanded its production capacity at its plant in Colorado, US to cater to the strong demand for cell and gene therapy.

Mar-2021: AGC expanded its geographical footprint by installing new viral vector production equipment at its facility in Milan, Italy. The new equipment would allow AGC to implement a platform best suited for the large-scale manufacturing of viral vectors.

Scope of the Study

Market Segments covered in the Report:

By Indication

Oncology

Cardiology

Central Nervous System & Musculoskeletal

Infectious Disease

Dermatology

Endocrine, Metabolic, Genetic

Immunology & Inflammation

Ophthalmology

Hematology

Gastroenterology

Others

By Product

Gene Therapy

Cell Therapy

Tissue Engineered & Others

By Phase

Phase I

Phase II

Phase III

Phase IV

By Geography

North America

o US

o Canada

o Mexico

o Rest of North America

Europe

o Germany

o UK

o France

o Russia

o Spain

o Italy

o Rest of Europe

Asia Pacific

o China

o Japan

o India

o South Korea

o Singapore

o Malaysia

o Rest of Asia Pacific

LAMEA

o Brazil

o Argentina

o UAE

o Saudi Arabia

o South Africa

o Nigeria

o Rest of LAMEA

Companies Profiled

Thermo Fisher Scientific, Inc. (Patheon, Inc.)

See the original post here:
The Global Advanced Therapy Medicinal Products CDMO Market ... - GlobeNewswire